Market cap $35 M /2 Approvals expected next month Cipher pharma (CPH.TO / CPHRF) (Market cap $35 M) Cash $10 M /Shares Out 26M / Profitable Pharma / 2 Drug Approvals expected next month /undiscovered Low Float stock / =Potential 10 Bagger here guys .GLTA Presentation https://filecache.investorroom.com/mr5ircnw_cipher/217/IR%20Deck%20May%202019%20Final.pdf Cipher Pharma anticipates several key milestones in 2019 that will continue the growth of its Canadian commercial platform, including: Regulatory approval for plecanatide from Health Canada in Q4 2019 ($200+ Million Market) Regulatory approval for A-101 from Health Canada in Q4 2019 ($100+ Million Market) Commercial launch of XYDALBA (dalbavancin) ($60 Million Market) North American top line results for MOB-015 in Q4 2019